Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

Frontiers in immunology·2026

Same author

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

JAMA dermatology·2026

Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026

Same author

Rapid Affinity Characterization of Cell-Free Expressed Nanobodies Directly in Lysate with Biolayer Interferometry via Antigen-Immobilized Biosensors.

ACS synthetic biology·2026

Same author

Somatostatin Receptor Expression on [<sup>68</sup>Ga]Ga-DOTATATE PET Among Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas: A Prospective Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Search research articles

Related Experiment Video

Updated: Jan 3, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Development of Targeted Alpha Particle Therapy for Solid Tumors.

Narges K Tafreshi¹, Michael L Doligalski¹, Christopher J Tichacek¹

¹Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

Molecules (Basel, Switzerland)

|November 30, 2019

Summary

Targeted alpha-particle therapy (TAT) uses alpha-emitting radionuclides to precisely target cancer cells, offering potent tumor damage with minimal harm to healthy tissues. Recent studies highlight TAT's significant success in treating advanced prostate cancer.

Keywords:

chelation clinical studies mechanism of cell death medicinal chemistry radiation dosimetry solid tumors targeted alpha-particle therapy targeting moieties

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

Related Experiment Videos

Last Updated: Jan 3, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

Area of Science:

Oncology
Nuclear Medicine
Radiopharmaceutical Chemistry

Background:

Targeted alpha-particle therapy (TAT) utilizes alpha-emitting radionuclides for cancer treatment.
Alpha particles offer high linear energy transfer (LET) and short tissue range, maximizing tumor cell damage while sparing healthy tissues.
Recent clinical trials show promising efficacy of TAT for metastatic castration-resistant prostate cancer.

Purpose of the Study:

To provide a comprehensive review of targeted alpha-particle therapy.
To discuss key aspects including radionuclide properties, therapeutic mechanisms, targeting strategies, dosimetry, and optimization.
To summarize preclinical and clinical applications of TAT.

Main Methods:

Review of current literature on alpha-particle-emitting radionuclides and their clinical relevance.
Analysis of TAT mechanisms, targeting moieties, and radiometal chelators.
Discussion of radiation dosimetry calculations and medicinal chemistry approaches for lead optimization.
Summary of preclinical and clinical study outcomes.

Main Results:

TAT demonstrates significant potential due to the cytotoxic payload of alpha particles and targeted delivery systems.
Various radionuclides, targeting moieties, and chelators are available for TAT development.
Accurate dosimetry and medicinal chemistry are crucial for optimizing TAT efficacy and safety.
TAT has shown remarkable efficacy in treating metastatic castration-resistant prostate cancer.

Conclusions:

Targeted alpha-particle therapy is a highly effective cancer treatment modality, particularly for advanced prostate cancer.
Continued research in radionuclide selection, targeting strategies, and optimization is essential for advancing TAT.
TAT represents a promising frontier in precision oncology, minimizing off-target toxicity.